Cardiovascular Diabetology

1. Cardiovasc Diabetol18 Nov 2025

   Impact of left ventricular dilatation on biventricular function and deformation in diabetes mellitus with reduced ejection fraction: a CMR feature tracking study

   Cross-sectional studyT2D & other

2. Cardiovasc Diabetol18 Nov 2025

   Distinct immune-metabolic phenotypes underlie poor coronary collateral circulation

   Cross-sectional study

3. Cardiovasc Diabetol17 Nov 2025

   Association of cumulative changes in atherogenic index of plasma and its obesity-related derivatives with cardiovascular disease: emphasis on incremental risk of diabetes status

   Cohort studyObesity

4. Cardiovasc Diabetol14 Nov 2025

   Precision integrated identification of predictive first-trimester metabolomics signatures for early detection of gestational diabetes mellitus

   Case-control studyDiabetes in pregnancy

5. Cardiovasc Diabetol14 Nov 2025

   Favorable outcomes of SGLT2 inhibitor use in pacemaker recipients: a population-based study

   Cohort studyT2D & other

6. Cardiovasc Diabetol14 Nov 2025

   A glucose time in range of 70% attenuates the senescence-inducing and pro-inflammatory effects of hyperglycemia

   Mechanistic studyT1D

7. Cardiovasc Diabetol12 Nov 2025

   Associations of longitudinal trajectories of triglyceride-glucose index combined with classical and novel obesity indices and cardiovascular disease: evidence from a nationwide prospective cohort study in China

   Cohort studyObesity

8. Cardiovasc Diabetol12 Nov 2025

   Proteome organ aging and cardiometabolic risk in a population at risk for heart failure

   Cross-sectional study

9. Cardiovasc Diabetol11 Nov 2025

   A six-year longitudinal study identifies a statin-independent association between low LDL-cholesterol and risk of type 2 diabetes

   Cohort studyT2D & other

10. Cardiovasc Diabetol11 Nov 2025

    Artificial intelligence identifies individuals with prediabetes using single-lead electrocardiograms

    Diagnostic or prognostic studyT2D & other

11. Cardiovasc Diabetol10 Nov 2025

    Electronic nose for detecting abnormal glucose metabolism in heart transplant recipients

    Diagnostic or prognostic studyT2D & other

12. Cardiovasc Diabetol7 Nov 2025

    Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study

    Cohort studyT2D & other

13. Cardiovasc Diabetol6 Nov 2025

    Sex differences in the prognostic value of urinary albumin-to-creatinine ratio for coronary artery disease and cardiovascular events in people with type 2 diabetes and normoalbuminuria

    Cohort studyT2D & other

14. Cardiovasc Diabetol5 Nov 2025

    Increased high-risk plaque burden in type 2 diabetes: a 10-year follow-up study

    Cohort studyT2D & other

15. Cardiovasc Diabetol5 Nov 2025

    Stress hyperglycemia ratio modulates the impact of organ dysfunction on mortality risk in critically ill patients with atrial fibrillation: insights from the MIMIC-IV database

    Cohort study

16. Cardiovasc Diabetol4 Nov 2025

    Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives

    Secondary analysisT2D & other

17. Cardiovasc Diabetol4 Nov 2025

    Elevated triglyceride-glucose index and its combination with anthropometric indices as indicators of the risk of new-onset transient ischemic attack: a prospective cohort study

    Cohort studyLipids & liver

18. Cardiovasc Diabetol3 Nov 2025

    HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study

    Secondary analysisT2D & other

19. Cardiovasc Diabetol31 Oct 2025

    Benefits of glucagon-like peptide-1 receptor agonists versus pioglitazone for cardio-hepatic outcomes: a territory-wide target trial emulation

    Cohort studyT2D & other

20. Cardiovasc Diabetol29 Oct 2025

    Associations between triglyceride-glucose-related indices and all-cause and cardiovascular mortality among individuals with atrial fibrillation and metabolic syndrome: a cohort study of the UK biobank

    Cohort studyLipids & liver

21. Cardiovasc Diabetol28 Oct 2025

    Association between the stress hyperglycemia ratio and elevated blood pressure among U.S. adolescents aged 12–17

    Cross-sectional study

22. Cardiovasc Diabetol28 Oct 2025

    Prognostic role of sarcopenia in heart failure patients

    Cohort study

23. Cardiovasc Diabetol28 Oct 2025

    The relationship between C-reactive protein-triglyceride-glucose index and cardiovascular disease: insights from the China health and retirement longitudinal study (CHARLS)

    Cohort study

24. Cardiovasc Diabetol28 Oct 2025

    Evaluation of four insulin resistance surrogate indicators for predicting short-term mortality in critically ill patients with ischemic stroke: a nationwide retrospective cohort study

    Cohort study

25. Cardiovasc Diabetol25 Oct 2025

    Insulin resistance-related indices, genetic risk, and the risk of cardiovascular disease in individuals with preclinical or clinical obesity: a large prospective cohort study in the UK biobank

    Cohort studyObesity

26. Cardiovasc Diabetol24 Oct 2025

    Interplay of glycated hemoglobin and traditional risk factors for the risk of atherosclerotic cardiovascular disease and all-cause mortality in people without diabetes

    Meta-analysis

27. Cardiovasc Diabetol24 Oct 2025

    High predicted cardiac event risk in youth with obesity and type 2 diabetes: a pooled cohort analysis

    Cross-sectional studyT2D & other

28. Cardiovasc Diabetol22 Oct 2025

    The prognostic value of atherogenic index of plasma and thin-cap fibroatheroma among patients with STEMI: an optical coherence tomography prospective cohort study of real world

    Cohort studyLipids & liver

29. Cardiovasc Diabetol22 Oct 2025

    AI-quantified epicardial adipose tissue and prediction of future myocardial infarction in patients with cardiometabolic disease: a post-hoc analysis from the SCOT-HEART trial

    Secondary analysis

30. Cardiovasc Diabetol22 Oct 2025

    Association of estimated glucose disposition rate with aging acceleration and mortality risk in individuals with cardiovascular-kidney-metabolic syndrome: evidence from two large national population-based studies

    Cohort study

31. Cardiovasc Diabetol17 Oct 2025

    Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods

    Meta-analysisT2D & other

32. Cardiovasc Diabetol15 Oct 2025

    Epicardial adipose tissue volume and arterial stiffness in people living with diabetes: the METAB-CV-PWV study

    Cohort studyT2D & other

33. Cardiovasc Diabetol15 Oct 2025

    Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers

    Randomized controlled trialLipids & liver

34. Cardiovasc Diabetol15 Oct 2025

    The role of insulin resistance in the longitudinal progression from NAFLD to cardiovascular-kidney-metabolic disease

    Cohort studyLipids & liver

35. Cardiovasc Diabetol14 Oct 2025

    Genetic variation in the glucagon-like peptide-1 receptor protein encoding region is associated with higher heart rate variability, but not with neurodegeneration of the brain, retina, and peripheral nerves: The Maastricht study

    Cohort studyT2D & other

36. Cardiovasc Diabetol11 Oct 2025

    Cardio-kidney-metabolic complexity in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF registry phase III

    Cohort study

37. Cardiovasc Diabetol11 Oct 2025

    Impact of glucometabolic status on type 4a myocardial infarction in patients with non–ST-segment elevation myocardial infarction: the role of stress hyperglycemia ratio

    Cohort studyComplications

38. Cardiovasc Diabetol11 Oct 2025

    Association between cholesterol, high-density lipoprotein, and glucose index and risks of cardiovascular and all-cause mortality in patients with calcific aortic valve stenosis: the ARISTOTLE cohort study

    Cohort study

39. Cardiovasc Diabetol10 Oct 2025

    Prognostic value of glycaemic variability for mortality in cardiogenic shock patients: a retrospective cohort study

    Cohort study

40. Cardiovasc Diabetol10 Oct 2025

    Association between atherogenic index of plasma (AIP) and all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a cohort study based on NHANES 1999–2018

    Cohort studyLipids & liver

All 1,291 Briefs in ExploreShowing Briefs 281–320 of 1,291, newest first